The TAXUS Liberte Stent employs an advanced stent design for more consistent drug distribution and greater stent deliverability to the target lesion. When compared to the TAXUS Express® Stent, Boston Scientific's TAXUS Liberte Stent features a hybrid cell design with more uniform stent architecture, a 27 percent reduction in strut thickness and superior results when treating patients with small diameter vessels or long lesions, as demonstrated in the TAXUS ATLAS Small Vessel and Long Lesion studies.
The primary investigators of the TAXUS Liberte study are Kirk Garratt, M.D., from Lenox Hill Hospital in New York, and David P. Lee, M.D., from Stanford University Medical Center.
Ad Statistics
Times Displayed: 22348
Times Visited: 450 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Effient® is a registered trademark of Eli Lilly and Company.
The TAXUS Liberte Stent received CE Mark approval in 2005, U.S. FDA approval in 2008 and Japanese approval in 2009.
About the DAPT Study
The DAPT Study is an independently managed, large-scale study designed to investigate the benefits of 12 versus 30 months of dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication to reduce the risk of blood clots) to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents.
The DAPT Study concept was developed by a group of major stent manufacturers and the manufacturers of thienopyridine/antiplatelet medications who came together to address an FDA request for this post-market study. The Harvard Clinical Research Institute (www.hcri.harvard.edu) is responsible for the scientific conduct and independent analysis of the overall study.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Back to HCB News
